Gilead Sciences, Inc. (GILD)
A forensic read on Gilead Sciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
Gilead Sciences, Inc. Is a biopharmaceutical company focused on developing and delivering innovative medicines for life-threatening diseases, including HIV, viral hepatitis, covid-19, and cancer, operating in over 35 countries. Revenue grew from $28.75B in FY2024 to $29.44B in FY2025, a 2.4% increase, while net margin expanded from 1.7% to 28.9% over the same period.
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Gilead Sciences, Inc.'s actual 10-K/10-Q/8-K filings?
Generate the AI investment read →No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Sep 22, 2026. Forensic signals flag probability, not certainty.